Description

The COVID-19 pandemic has impacted the global supply of nucleic acid products including mRNA and plasmid DNA and delivery vehicles such as lipid nanoparticles which have been demonstrated to be important tools for outbreak management predominately via a mass vaccination approach. The time to market for these products is hindered by complexities in production, production processes, analytical methods, and complicated supply chain, intellectual property landscape and quality management systems. Northern RNA's intention is to provide agile platform production approaches and enabling systems, infrastructure, and resources to ensure access to nucleic acid products and their formulations for researchers, organizations, and healthcare providers in managing the current pandemic and to heighten domestic and global preparedness for the future.

Expected Results

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Recipient

NORTHERN RNA INC.

Operating as: Northern RNA Inc.

Location

Calgary, AB T2A 7H8

Agreement Details

Number: 1003190

Reference: 172-2022-2023-Q4-1003190

Timeline

Start: July 28, 2022

End: March 22, 2024

Program

Industrial Research Assistance Program Contributions to Firms

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …

Sector

Manufacturing (3254)